Ticker Launch
Sign inGet notified

IPO · GRPH

LENZ Therapeutics, Inc.

Formerly Graphite Bio, Inc.

LENZ Therapeutics, Inc. (GRPH) priced its initial public offering on Jun 28, 2021 at $17.00 per share, raising $238M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $951.6M. BofA Securities was lead-left underwriter, joined by Morgan Stanley, Leerink Partners and TD Cowen. Goodwin Procter advised the company and Cooley advised the underwriters.

At its 2021 IPO, Graphite Bio (now LENZ Therapeutics) was a clinical-stage gene editing company using targeted gene integration to develop therapies for serious diseases. Its lead program, GPH101, was in early clinical development.

Status
IPO
Ticker
GRPH
Exchange
Nasdaq Global Market
Priced
Jun 28, 2021
IPO price
$17.00
Raised
$238M
Market cap at IPO price
$951.6M
First filed
Jun 4, 2021
Underwriters
BofA Securities, Morgan Stanley, Leerink Partners and TD Cowen
Company counsel
Goodwin Procter
Underwriters' counsel
Cooley
Sector
Biotech & pharma
Country / state
CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.

More on this listing for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Get notified at launchOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other Biotech & pharma IPOs in 2021